Metastatic Sarcoma

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Metastatic Sarcoma is an early-stage landscape with 0 programs across 2 companies. The most active players are Tracon Pharmaceuticals Inc., MabVax Therapeutics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Tracon Pharmaceuticals Inc.

0 programs

Preclinical M

MabVax Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Completed10 · 56%

Unknown status3 · 17%

Recruiting2 · 11%

Terminated2 · 11%

Active, not recruiting1 · 6%

Clinical Trials

Trial Activity

18 trials

BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma

Recruiting·RRuijin Hospital·Phase 2·NCT04072042·30 enrolled

Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Preclinical·NCT06796543·70 enrolled

Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma

Active, not recruiting·UUniversity of California, Irvine·Phase 1·NCT05488366·9 enrolled

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT04076579·29 enrolled

Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery

Completed·National Cancer Institute (NCI)·Phase 2·NCT02500797·164 enrolled

Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04242238·32 enrolled

Alisertib in Treating Patients With Advanced or Metastatic Sarcoma

Completed·National Cancer Institute (NCI)·Phase 2·NCT01653028·72 enrolled

Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery

Completed·WWake Forest University Health Sciences·Phase 2·NCT01553539·20 enrolled

A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas

Completed·NNCIC Clinical Trials Group·Phase 2·NCT01112384·24 enrolled

Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00027716

Mix Vaccine for Metastatic Sarcoma Patients

Completed·FFuda Cancer Hospital, Guangzhou·Phase 1/2·NCT03357315·30 enrolled

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

Completed·National Cancer Institute (NCI)·Phase 1/2·NCT01154452·78 enrolled

Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

Completed·MMabVax Therapeutics, Inc.·Phase 2·NCT01141491·136 enrolled

Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients

Terminated·TThe Netherlands Cancer Institute·Phase 2·NCT02575066·25 enrolled

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

Terminated·National Cancer Institute (NCI)·Phase 1/2·NCT02601209·151 enrolled

Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)